Drugs / ABBV-291
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06667687 | Jan 2025 → Jan 2027 expected | non-Hodgkin lymphoma | AbbVie | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ABBV-291 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06667687 ↗ |
| Route | Intravenous | “Intravenous Infusion” NCT06667687 ↗ |